AKT1 and acute myeloid leukemia: In this respect, recent experimental and clinical studies underscore that inhibitors of DDR and PI3K/AKT signaling pathways including FLT3 inhibitors should be administered simultaneously rather than sequentially with chemotherapy/HMAs to potentiate rather than complement therapeutic efficacy, as is the case with AML treatment regimens and ongoing trials combining standard AML chemotherapy with sequential inhibitor administration[73,75].